Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries

Abstract

BACKGROUND Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to understand antifibrotic prescribing and identify unmet needs in… (More)
DOI: 10.1186/s12890-017-0468-5

Topics

8 Figures and Tables

Blog articles referencing this paper

Slides referencing similar topics